Therapeutic Effects of Maternal Melatonin Administration on Brain Injury and White Matter Disease
Status:
Terminated
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
Neurocognitive sequelae observed in preterm represent a major health problem for which there
is no preventive treatment approved to date. These effects are the result of a multifactorial
brain damage occurring in developing prenatal and perinatal period. Melatonin, the principal
hormone secreted by the pineal gland has neuroprotective properties in various experimental
animal models of perinatal brain damage level. This hormone readily crosses the placental
barrier, its antenatal administration would have a neuroprotective effect in the case of
preventive preterm birth before 28 weeks of amenorrhea.
The objective of this study determine the dose of melatonin administered parenterally in
prenatal maternal in preterm labor to reduce brain damage in the white matter detected by
diffusion tensor imaging (DTI) with statistical spatial analysis (TBSS) to the theoretical
term of 40 weeks in children born prematurely.